Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

15
Buy This Cybersecurity ETF Before Midterms

2h seekingalpha
We're increasingly living in a digital world where securing all of our personal information and data is becoming top priority.
SPLK SYMC MU PANW CSCO MYGN VMW

4
Myriad Announces Coverage Decision by Kroger® Prescription Plans for Vectra DA®

2018-07-18 globenewswire
SALT LAKE CITY, July 18, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced that Kroger Prescription Plans, will provide Vectra® DA as a benefit option for Kroger Prescription Plan employer group clients.
KR MYGN

2
Top-Five National Payer Issues Positive Coverage Decision for Myriad’s Prolaris® Test for Prostate Cancer

2018-06-21 globenewswire
SALT LAKE CITY, June 21, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has received a positive medical policy decision for its Prolaris® prostate cancer test from one of the nation’s top-five insurance companies. This positive coverage decision follows the recently updated National Comprehensive Cancer Network (NCCN) medical guidelines for prostate cancer, which support Prolaris as a standard-of-care genetic test for men diagnosed with low and favorable-intermediate risk prostate cancer.
MYGN

46
Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx

2018-06-19 zacks
Myriad Genetics, Inc. (MYGN - Free Report) has moved one step forward in acquiring the FDA approval for the company’s BRACAnalysis CDx test to be used as a companion diagnostic with Pfizer’s (PFE - Free Report) PARP inhibitor, talazoparib. The company noted that the FDA has accepted its supplementary premarket approval (sPMA) application for BRACAnalysis CDx, which can help identifying the best responders to talazoparib.
AZN AZN MYGN PFE

2
Myriad’s BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Talazoparib in Metastatic Breast Cancer

2018-06-18 globenewswire
SALT LAKE CITY, June 18, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplementary premarket approval (sPMA) application for BRACAnalysis CDx® to be used as a companion diagnostic with Pfizer’s PARP (poly ADP ribose polymerase) inhibitor, talazoparib.
MYGN

647
Stocks To Watch: Focus On E3, IHOP/b And The World Cup

2018-06-09 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
GOOS GNK AINC CAT TWX O.PRF DXCM MS.PRE PGR MS.PRF MS.PRG RH AXDX] OPRF MS.PRA AJG NKE SHAK AMZN SCVL AEP MYGN DCI MS VLKAY JBL SCHW.PRBCL TTWO CARB TREX FAST INCY PDYPF COMM AXDX NVMI TWC AVT MS.PRI MS.PRK RNG PAP AHBIF MSFT NFG PEG HRB PDYPY NMRK ULTA ADDYY ADP WDAY CASA ADBE GMVHF ATVI CGBD AMTD LII PRTY DIN EXC NEE DIS LUV EA ALGN AEP.PRA BUD CMCSA O NEO FDX KFY RGEN EXAS FNSR NEE.PRI XEL NEE.PRJ SIX TGT SCHW T ADPVV ETFC NEE.PRC NEE.PRQ NEE.PRR SNE PLAY CAKE CODI

642
Stocks To Watch: Focus On E3, IHopb And The World Cup

2018-06-09 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
GOOS GNK AINC CAT TWX O.PRF DXCM MS.PRE PGR MS.PRF MS.PRG RH AXDX] OPRF MS.PRA AJG NKE SHAK AMZN SCVL AEP MYGN DCI MS VLKAY JBL SCHW.PRBCL TTWO CARB TREX FAST INCY PDYPF COMM AXDX NVMI TWC AVT MS.PRI MS.PRK RNG PAP AHBIF MSFT NFG PEG HRB PDYPY NMRK ULTA ADDYY ADP WDAY CASA ADBE GMVHF ATVI CGBD AMTD LII PRTY DIN EXC NEE DIS LUV EA ALGN AEP.PRA BUD CMCSA O NEO FDX KFY RGEN EXAS FNSR NEE.PRI XEL NEE.PRJ SIX TGT SCHW T ADPVV ETFC NEE.PRC NEE.PRQ NEE.PRR SNE PLAY CAKE CODI

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to MYGN / Myriad Genetics, Inc. on message board site Silicon Investor.

Myriad Genetics, Inc. (MYGN) MYGN
CUSIP: 62855J104